Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 18 04:00PM ET
7.24
Dollar change
-0.38
Percentage change
-4.99
%
IndexRUT P/E- EPS (ttm)-2.38 Insider Own17.41% Shs Outstand113.86M Perf Week-0.28%
Market Cap824.32M Forward P/E- EPS next Y-1.89 Insider Trans0.22% Shs Float94.03M Perf Month45.38%
Income-256.98M PEG- EPS next Q-0.58 Inst Own100.06% Short Float15.21% Perf Quarter-1.96%
Sales0.00M P/S- EPS this Y10.00% Inst Trans17.37% Short Ratio9.29 Perf Half Y-11.17%
Book/sh0.97 P/B7.44 EPS next Y14.74% ROA-70.93% Short Interest14.31M Perf Year-14.07%
Cash/sh2.16 P/C3.36 EPS next 5Y29.85% ROE-84.04% 52W Range3.72 - 12.61 Perf YTD-7.18%
Dividend Est.- P/FCF- EPS past 5Y10.02% ROIC-109.60% 52W High-42.59% Beta1.84
Dividend TTM- Quick Ratio5.13 Sales past 5Y- Gross Margin- 52W Low94.62% ATR (14)0.49
Dividend Ex-Date- Current Ratio5.13 EPS Y/Y TTM4.02% Oper. Margin- RSI (14)65.60 Volatility4.64% 5.13%
Employees205 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.55 Target Price16.30
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q14.72% Payout- Rel Volume2.00 Prev Close7.62
Sales Surprise- EPS Surprise-7.17% Sales Q/Q- EarningsMay 06 BMO Avg Volume1.54M Price7.24
SMA2017.23% SMA5035.52% SMA200-11.08% Trades Volume3,076,344 Change-4.99%
Date Action Analyst Rating Change Price Target Change
Mar-07-25Initiated Scotiabank Sector Outperform $17
Dec-11-24Downgrade Needham Buy → Hold
Feb-26-24Downgrade Robert W. Baird Outperform → Neutral $14 → $8
Feb-08-24Initiated Citigroup Buy $11
Dec-11-23Downgrade Wedbush Outperform → Neutral $5
Dec-08-23Initiated JP Morgan Overweight $18
Apr-28-23Initiated Robert W. Baird Outperform $20
Mar-27-23Resumed H.C. Wainwright Buy $28
Dec-14-22Initiated Needham Buy $24
Jun-28-22Initiated Guggenheim Buy $15
Jun-11-25 08:00AM
May-29-25 08:00AM
May-13-25 09:55AM
08:50AM
May-06-25 08:00AM
07:57AM Loading…
May-05-25 07:57AM
Apr-25-25 08:08AM
Apr-20-25 06:16AM
Apr-16-25 10:03AM
Apr-09-25 04:28PM
Mar-25-25 04:31PM
Mar-20-25 08:32AM
Mar-07-25 08:00AM
Feb-27-25 08:00AM
Feb-25-25 08:00AM
09:15AM Loading…
Feb-10-25 09:15AM
Jan-30-25 08:00AM
Jan-13-25 08:00AM
Jan-08-25 08:00AM
Dec-09-24 07:00AM
Dec-08-24 12:00PM
Nov-05-24 09:00AM
Oct-23-24 07:00AM
Oct-09-24 08:03AM
Sep-03-24 08:00AM
Sep-02-24 05:22PM
Aug-06-24 08:00AM
Jun-28-24 09:18AM
Jun-27-24 08:00AM
Jun-14-24 07:30AM
05:05PM Loading…
May-23-24 05:05PM
05:01PM
May-07-24 01:52PM
08:00AM
Apr-09-24 09:00AM
Mar-13-24 07:06AM
Feb-28-24 04:32AM
Feb-26-24 08:00AM
Feb-22-24 02:30PM
Feb-14-24 07:00AM
Feb-05-24 09:00AM
Jan-09-24 08:00AM
Jan-02-24 08:00AM
Dec-11-23 07:55AM
Dec-09-23 01:30PM
Dec-07-23 09:00AM
Dec-04-23 08:00AM
Nov-29-23 08:00AM
Nov-02-23 09:00AM
Oct-14-23 12:30PM
Aug-13-23 08:51AM
Aug-08-23 08:00AM
Jul-10-23 07:35PM
Jun-09-23 04:01PM
Jun-07-23 09:00AM
Jun-06-23 08:25PM
04:05PM
Jun-03-23 02:15PM
May-23-23 08:00AM
May-09-23 08:00AM
Apr-17-23 09:00AM
Apr-12-23 08:00AM
Mar-14-23 08:00AM
Feb-01-23 08:00AM
Jan-11-23 11:03AM
Jan-09-23 08:00AM
Jan-05-23 08:00AM
Dec-11-22 05:30PM
Dec-05-22 08:00AM
Nov-28-22 04:15PM
Nov-14-22 07:00AM
Nov-09-22 08:00AM
Nov-03-22 09:05AM
Oct-26-22 07:00AM
Aug-14-22 12:21PM
Aug-09-22 07:00AM
Aug-04-22 11:22AM
Jun-20-22 11:09AM
Jun-16-22 04:01PM
Jun-13-22 09:48PM
06:00AM
Jun-10-22 07:00AM
Jun-06-22 10:15AM
Jun-02-22 08:00AM
May-12-22 10:00AM
May-10-22 07:00AM
May-06-22 08:00AM
Apr-11-22 07:00AM
Mar-29-22 07:00AM
Mar-15-22 07:00AM
Mar-08-22 05:10PM
Feb-01-22 05:29AM
Jan-05-22 07:00AM
Nov-22-21 07:00AM
Nov-10-21 07:00AM
Nov-02-21 07:00AM
Oct-29-21 09:46AM
Oct-12-21 07:59PM
Oct-07-21 09:00AM
Oct-01-21 07:00AM
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pinnow ColeChief Commercial OfficerJan 14 '25Buy7.6043,750332,41245,848Jan 15 07:00 AM